Thursday, January 23, 2025

Healthcare

NurExone’s Game-Changing Moves in Biopharmaceuticals and Exosome Technology (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)

NurExone (TSXV: NRX) (Germany: J90)  (the “Company” or “NurExone") is a pioneering biopharmaceutical company developing regenerative medicine therapies. For a quick catch up on NRX, here are...

Exploring RenovoRx’s Breakthroughs in Targeted Cancer Treatments

RenovoRx’s TAMP™ platform significantly increases local tissue concentration of chemotherapy, potentially reducing systemic side effects and enhancing treatment efficacy. The Phase III TIGeR-PaC clinical trial...

RenovoRx’s TAMP Platform Revolutionizes Cancer Therapy (Nasdaq: RNXT)

 ("RenovoRx" or the "Company") (Nasdaq: RNXT), is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform.  Recently, the Company announced the...

NurExone’s Expands Commercialization Efforts with All-star Hire (TSXV: NRX)

NurExone (TSXV: NRX) (Germany: J90)  (the “Company” or “NurExone") is a pioneering biopharmaceutical company developing regenerative medicine therapies. For a quick catch up on NRX, here are...

Nurexone is on a Quest to Revolutionize Spinal Cord Injury Treatment

Nurexone Biologic Inc. leads the charge in developing cutting-edge exosome-based therapies for central nervous system injuries, particularly traumatic spinal cord injuries (tSCI), promising groundbreaking...

Popular

Subscribe